Additive renoprotective effects of B2-kinin receptor blocker and PPAR-γ agonist in uninephrectomized db/db mice

Laboratory Investigation

Volumn 91, Issue 9, 2011, Pages 1351-1362

  Tang, Sydney C W ^a   Chan, Loretta Y Y ^a   Leung, Joseph C K ^a   Cheng, Amy Shan ^a   Lan, Hui Yao ^b   Lai, Kar Neng ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

B2 kinin receptor blockade; diabetic nephropathy; inflammation; PPAR g agonist; renal pathology; signaling; uninephrectomy

Indexed keywords

BRADYKININ B2 RECEPTOR ANTAGONIST; CREATININE; ICATIBANT; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE SEVERITY; DRUG EFFECT; EXPERIMENTAL RAT; FIBROSIS; GLYCEMIC CONTROL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KALLIKREIN KININ SYSTEM; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; SHAM PROCEDURE; TREATMENT DURATION;

ANIMALS; BLOTTING, WESTERN; IMMUNOHISTOCHEMISTRY; KIDNEY; MICE; MICE, INBRED STRAINS; NEPHRECTOMY; PPAR GAMMA; RECEPTOR, BRADYKININ B2;

EID: 80052296926     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.81     Document Type: Article

References (27)

1. Kakoki M, Smithies O. The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int 2009;75:1019-1030.
2. Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004;3:845-852. (Pubitemid 39405945)
3. Tang SC, Chan LY, Leung JC, et al. Bradykinin and high glucose promote renal tubular inflammation. Nephrol Dial Transplant 2010;25:698-710.
4. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-895.
5. Tang SC, Leung JC, Chan LY, et al. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferatoractivated receptor-{gamma} agonist. J Am Soc Nephrol 2006;17: 1633-1643. (Pubitemid 43794666)
6. Tang SC, Leung JC, Chan LY, et al. Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: role of STAT1 inhibition and nephrin restoration. Am J Nephrol 2010;32:145-155.
7. Tang SC, Leung JC, Chan LY, et al. Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy. Kidney Int 2008;73:288-299.
8. Campbell DJ, Kladis A, Zhang Y, et al. Increased tissue kallikrein levels in type 2 diabetes. Diabetologia 2010;53:779-785.
9. Alric C, Pecher C, Cellier E, et al. Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin. Kidney Int 2002;62:412-421. (Pubitemid 34779752)
10. Pawluczyk IZ, Patel SR, Harris KP. The role of bradykinin in the antifibrotic actions of perindoprilat on human mesangial cells. Kidney Int 2004;65:1240-1251. (Pubitemid 38406962)
11. Kakoki M, Takahashi N, Jennette JC, et al. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 2004;101:13302-13305. (Pubitemid 39209660)
12. Kakoki M, Kizer CM, Yi X, et al. Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest 2006;116:1302-1309.
13. Tschope C, Seidl U, Reinecke A, et al. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy. Int Immunopharmacol 2003;3:335-344. (Pubitemid 36293962)
14. Bodin S, Chollet C, Goncalves-Mendes N, et al. Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int 2009;76:395-403.
15. Buleon M, Allard J, Jaafar A, et al. Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model. Am J Physiol Renal Physiol 2008;294:F1249-F1256.
16. Goldstein RH, Wall M. Activation of protein formation and cell division by bradykinin and des-Arg9-bradykinin. J Biol Chem 1984;259: 9263-9268. (Pubitemid 14098915)
17. Tan Y, Wang B, Keum JS, et al. Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am J Physiol Renal Physiol 2005;288:F483-F492. (Pubitemid 40279454)
18. Tan Y, Keum JS, Wang B, et al. Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol 2007;293:F1026-F1035. (Pubitemid 47583934)
19. Harvey JN, Jaffa AA, Margolius HS, et al. Renal kallikrein and hemodynamic abnormalities of diabetic kidney. Diabetes 1990;39: 299-304. (Pubitemid 20076212)
20. Zuccollo A, Frontera M, Cueva F, et al. Effects of aprotinin on the kallikrein-kinin system in type I diabetes (insulitis). Immunopharmacology 1997;37:251-256. (Pubitemid 27471042)
21. Zuccollo A, Navarro M, Catanzaro O. Effects of B1 and B2 kinin receptor antagonists in diabetic mice. Can J Physiol Pharmacol 1996;74: 586-589. (Pubitemid 26341482)
22. Duka I, Kintsurashvili E, Gavras I, et al. Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res 2001;88:275-281. (Pubitemid 32173750)
23. Griol-Charhbili V, Messadi-Laribi E, Bascands JL, et al. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 2005;19:1172-1174. (Pubitemid 40946455)
24. Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002;109:1057-1063. (Pubitemid 34408580)
25. Deeks ED. Icatibant. Drugs 2010;70:73-81.
26. Miyazaki Y, Cersosimo E, Triplitt C, et al. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007;72: 1367-1373. (Pubitemid 350126770)
27. Trivedi H, Lu N, Andresen BT, et al. Slower decline of renal function after initiation of rosiglitazone in diabetics-a pilot study. Clin Nephrol 2009;72:181-185.